Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data

◆ ◆ The Wire takeaway

FDA review windows can reopen with new data submissions, giving you a chance to extend regulatory timelines and revive stalled approvals. If you work in gene therapy or rare disease drug development, prepare for last-minute review opportunities that could change your go-to-market timing.